Novo Nordisk Faces Market Pressure Amid Regulatory Milestones and Analyst Downgrade
Published on 09/30/2025 at 18:54 | Redaktion boerse-global.de
Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent market conditions as competing forces shape its trajectory. While the company achieved a significant regulatory breakthrough with its weekly insulin treatment Awiqli, these gains were immediately overshadowed by a substantial equity downgrade from Morgan Stanley that sent shares downward.
Morgan Stanley’s decision to downgrade Novo Nordisk to “Underweight” status triggered an immediate market reaction, with shares declining more than 3% in a single trading session on Monday. The downward trend has persisted, contributing to a year-to-date loss exceeding 40% in shareholder value.
The investment bank justified its position by highlighting intensifying competition within the lucrative GLP-1 weight-loss medication sector. Rivals including Eli Lilly are increasingly encroaching on Novo Nordisk’s core... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
